Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance

Liver International

Volumn 33, Issue 4, 2013, Pages 642-646

  Lee, Guan Huei ^a,b   Inoue, Masafumi ^c   Toh, Jimmy K P ^c   Chong, Roxanne H H ^b   Aung, Myat Oo ^a   Koay, Evelyn S C ^b   Lim, Seng Gee ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Agency for Science   (Singapore)

Author keywords

Drug resistance; Hepatitis B

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; ENTECAVIR; ORAL ANTIDIABETIC AGENT; TENOFOVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CASE REPORT; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MOLECULAR PROBE; MONOTHERAPY; OBESITY; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; VIRUS STRAIN;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; GENOTYPE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; TIME FACTORS; TREATMENT FAILURE;

EID: 84875055213     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12104     Document Type: Article

References (18)

1. Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-5.
2. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
3. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 257-62.
4. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
5. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-5.
6. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
7. Lok ASF, McMahon BL. AASLD practice guidelines: Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-2.
8. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-34.
9. Hussain M, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44: 1094-97.
10. Kobachi H, Fujioka SI, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. HepatolInt 2009; 3: 404-10.
11. Suzuki F, Akuta N, Suzuki Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007; 39: 149-2.
12. Guo JJ, Li QL, Shi XF, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res 2009; 81: 180-3.
13. Lee HW, Kim HJ, Hong SP, et al. Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient. Intervirology 2012; 55: 380-4.
14. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 2012; 57: 508-14.
15. Kamezaki H, Kanda T, Wu S, et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol 2011; 46: 1111-7.
16. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7.
17. Baldick CJ, Egger BJ, Fang J, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J of Hepatol. 2008; 48: 895-902.
18. Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.